AGIOS PHARMACEUTICALS, INC.
Moat Score — Agios Pharmaceuticals, Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Agios holds strong patent protection and pioneering scientific know-how around pyruvate kinase activation, and PYRUKYND's first-in-class, FDA-approved status in PK deficiency represents a genuine, validated intangible asset built over more than a decade of focused metabolism research. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a specialty pharmaceutical company, Agios has no manufacturing scale cost advantage; its economics depend on drug pricing and R&D productivity rather than production cost efficiency. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As the first and, in PK deficiency, essentially only approved pyruvate kinase activator, Agios has strong pricing power typical of rare/orphan disease therapeutics, supported by limited direct competition in its initial approved indication. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in small-molecule pharmaceutical development and commercialization. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Hematologists and patients who have established a treatment routine on PYRUKYND face some switching costs given the drug's demonstrated efficacy and safety profile, though this is a moderate rather than extreme moat source typical of chronic rare-disease therapies. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The ultra-rare PK deficiency market is small enough that it does not attract broad competition, giving Agios an efficient-scale position in that specific indication, though this advantage is less pronounced as it expands into larger, more competitive indications like thalassemia and sickle cell disease. |